Product Images Opdivo

The provided text shows a graph with probability of survival on the y-axis and overall survival in months on the x-axis. However, some of the text is not properly recognized due to the error.*

This is a warning label for an intravenous medication called "nvokimad". It cautions users not to use if the bottle, carton, or seal is damaged, and to only use it as directed by a physician. The medication contains 100mg of nvokimad per 10 mL of solution, along with other ingredients. The label outlines storage instructions for the medication, such as refrigerating it between uses and avoiding shaking or freezing the bottle.*

This is a description for a medication provided in a single dose vial. The product should not be used if the vial seal is broken or missing, or if the carton or carton flaps are torn or ripped. The medication is produced by Bristol Myers Squibb and is for intravenous infusion only. It contains 120 mg of the drug in 12 mL of solution and is administered through an intravenous line. The medication includes several other ingredients to adjust its pH and maintain its stability. The medication must be infused within 24 hours of preparation, and it should be refrigerated between 2-5°C until use. The dosage and administration information is provided in the prescribing information.*

This is a description of a pharmaceutical product made by Bristol Myers Squibb CO. It contains a single-dose vial that is only for intravenous infusion. The product should not be used if the carton or carton flaps are torn or ripped. The ingredients include nivolumab, pentetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, and water for injection. The administration should be through an intravenous non-pyrogenic low-potency binding-filtration device and completed within 24 hours of preparation. The product should be stored in a refrigerator at 2°C-5°C and protected from light in its original package.*

This is a medication warning label for a 40 mg/4 ml vial of Nivolumab. It is for intravenous infusion only. The label warns against using the product if the carton or carton flaps are torn, missing, or ripped. The medication should be discarded after use, and it should be protected from light. Dosage information is provided in the prescribing information, and the medication should be administered through a non-pyrogenic, low protein binding inline filter. The medication should be stored at 2°C to 8°C and should not be frozen or shaken.*

Not available.*

This appears to be a statistical table or chart related to treatment outcomes with two drugs OPDIVO and Docetaxel. It includes information about PD-L1 expression and median time periods in months. However, due to the lack of context and clear readability, a detailed description cannot be provided.*

This is a study showing the median PFS (progression-free survival) in months for patients with PD-L1 expression level of 21% treated with OPDIVO and Docetaxel. The unstratified HR (hazard ratio) is also included in the table. However, no additional information or context is given, so it is unclear what the study is about or what the results mean.*

This appears to be a graph showing the probability of overall survival for subjects receiving OPDIVO in addition to chemotherapy versus those receiving only chemotherapy. The X-axis represents the number of subjects at specific time intervals and the Y-axis represents the duration of overall survival in months. The graph shows that the probability of overall survival is higher for subjects receiving OPDIVO in addition to chemotherapy compared to those receiving only chemotherapy. However, the data is truncated and incomplete as there is not enough information provided to interpret the graph accurately.*

This appears to be a table displaying the Probability of Survival for a particular study or clinical trial. The dates or years may be represented in the first column, with corresponding survival rates in the subsequent columns. There is a section header labeled "Investigator's Choice" which may refer to a specific treatment group or intervention. The last row contains numerical values for the number of subjects at risk and their overall survival, measured in months. The origin or context of the table is not clear.*

Not available.*

This is a chart that shows the probability of survival over a certain number of months for two different treatments: one with the drug Dacarbazine and another treatment labeled as TR. The chart has numbered intervals on the horizontal axis and months on the vertical axis. The TR treatment appears to have a slightly higher probability of survival at the beginning, but the Dacarbazine treatment becomes more effective after three months.*

This appears to be a table that compares the survival rates of several subjects using different treatments. The treatments being compared are OPDIVO, OPDIVO + Ipiimumab, and Iplimumab. The table shows the number of subjects at different overall survival months.*

The generated text is a chart depicting the overall survival rates in months for two treatment options, OPDIVO + ipilimumab and Sunitinib. The chart also shows the number of subjects at risk for each treatment option.*

This is a graph showing the probability of overall survival for two groups of subjects, one treated with OPDVO and ipilimumab and the other group with platinum-doublet chemotherapy. The X-axis represents the months elapsed since the start of treatment and the Y-axis represents the number of subjects who survived.*

This text provides data on the probability of overall survival in subjects treated with OPDIVO+ipilimumab and chemotherapy. The data includes the number of subjects at risk, overall survival (in months), and the treatment method used.*

The text provides a chart displaying the probability of progression-free survival per BICR for two treatments (OPDIVO + Cabozantinib and Sunitinib) over a period of months. The number of subjects at risk is also shown for each treatment. No further information is available.*

This appears to be a survival analysis table showing the probability of recurrence-free survival for subjects receiving treatment with ipilimumab. The table also includes the number of subjects at risk at each time point.*